Giorgio Gabarrini

Giorgio Gabarrini

Auto-generated profile, based on publicly available information

Giorgio Gabarrini

Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
GGGiorgio Gabarrini
Giorgio Gabarrini
Rick HeidaRick Heida
Rick Heida
NINienke van Ieperen
Nienke van Ieperen
MCMichael Curtis
Michael Curtis
AWArie Jan van Winkelhoff
Arie Jan van Winkelhoff
JDJan Maarten Van Dijl
Jan Maarten Van Dijl
The periodontal pathogen Porphyromonas gingivalis has been invoked in the autoimmune disease rheumatoid arthritis (RA). This association relates to the peptidylarginine deiminase of P. gingivalis (PPAD), an enzyme capable of citrullinating human proteins and potentially contributing to loss of tolerance to citrullinated proteins in RA. PPAD is both retained in the outer membrane (OM) of P. gingivalis cells and secreted into the extracellular milieu, where it is detected in a soluble form and in association with outer membrane vesicles (OMVs). Recent studies showed that certain P. gingivalis proteins are retained in the OM through modification with an A-type lipopolysaccharide (A-LPS). Here, we investigated the possible involvement of A-LPS modification in the association of PPAD to the OM and OMVs. The results indicate that the OM- and OMV-associated PPAD is A-LPS-modified. The modified PPAD species is of low abundance in particular clinical isolates of P. gingivalis, which is not due to defects in the overall synthesis of A-LPS-modified proteins but, rather, to particular traits of the respective PPAD proteins. Lastly, we show that OMV association protects the A-LPS-modified PPAD from proteolytic degradation. Altogether, our observations show that A-LPS modification contributes to OM(V) sorting and ‘protective secretion’ of PPAD.

20 January 2022 in Med
Verified
Journal Article
Open access
KHKatie Healy
Katie Healy
EPElisa Pin
Elisa Pin
PCPuran Chen
Puran Chen
GSGunnar Söderdahl
Gunnar Söderdahl
PNPiotr Nowak
Piotr Nowak
MCMargaret Sällberg Chen
Margaret Sällberg Chen
Immunocompromised individuals are highly susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Whether vaccine-induced immunity in these individuals involves oral cavity, a primary site of infection, is presently unknown. Immunocompromised patients (n = 404) and healthy controls (n = 82) participated in a prospective clinical trial (NCT04780659) encompassing two doses of the mRNA BNT162b2 vaccine. Primary immunodeficiency (PID), secondary immunodeficiencies caused by human immunodeficiency virus (HIV) infection, allogeneic hematopoietic stem cell transplantation (HSCT)/chimeric antigen receptor T cell therapy (CAR-T), solid organ transplantation (SOT), and chronic lymphocytic leukemia (CLL) patients were included. Salivary and serum immunoglobulin G (IgG) reactivities to SARS-CoV-2 spike were measured by multiplex bead-based assays and Elecsys anti-SARS-CoV-2 S assay. IgG responses to SARS-CoV-2 spike antigens in saliva in HIV and HSCT/CAR-T groups were comparable to those of healthy controls after vaccination. The PID, SOT, and CLL patients had weaker responses, influenced mainly by disease parameters or immunosuppressants. Salivary responses correlated remarkably well with specific IgG titers and the neutralizing capacity in serum. Receiver operating characteristic curve analysis for the predictive power of salivary IgG yielded area under the curve (AUC) = 0.95 and positive predictive value (PPV) = 90.7% for the entire cohort after vaccination. Saliva conveys vaccine responses induced by mRNA BNT162b2. The predictive power of salivary spike IgG makes it highly suitable for screening vulnerable groups for revaccination. Knut and Alice Wallenberg Foundation, Erling Perssons family foundation, Region Stockholm, Swedish Research Council, Karolinska Institutet, Swedish Blood Cancer Foundation, PID patient organization of Sweden, Nordstjernan AB, Center for Medical Innovation (CIMED), Swedish Medical Research Council, and Stockholm County Council (ALF).

20 December 2023 in npj Biofilms and Microbiomes
Verified
Journal Article
Open access
PDF file
SRShilpa Ray
Shilpa Ray
ANAswathy Narayanan
Aswathy Narayanan
JVJan Vesterbacka
Jan Vesterbacka
OBOla Blennow
Ola Blennow
PCPuran Chen
Puran Chen
PNPiotr Nowak
Piotr Nowak
Although mRNA SARS-CoV-2 vaccines are generally safe and effective, in certain immunocompromised individuals they can elicit poor immunogenic responses. Among these individuals, people living with HIV (PLWH) have poor immunogenicity to several oral and parenteral vaccines. As the gut microbiome is known to affect vaccine immunogenicity, we investigated whether baseline gut microbiota predicts immune responses to the BNT162b2 mRNA SARS-CoV-2 vaccine in healthy controls and PLWH after two doses of BNT162b2. Individuals with high spike IgG titers and high spike-specific CD4+ T-cell responses against SARS-CoV-2 showed low α-diversity in the gut. Here, we investigated and presented initial evidence that the gut microbial composition influences the response to BNT162b2 in PLWH. From our predictive models, Bifidobacterium and Faecalibacterium appeared to be microbial markers of individuals with higher spike IgG titers, while Cloacibacillus was associated with low spike IgG titers. We therefore propose that microbiome modulation could optimize immunogenicity of SARS-CoV-2 mRNA vaccines.

13 November 2021
Verified
Book Chapter
Closed access
YFYanyan Fu
Yanyan Fu
ARAnna Haider Rubio
Anna Haider Rubio
CGCostanza Gscheider
Costanza Gscheider
MEMarines du Teil Espina
Marines du Teil Espina
RFRosario Flores-Vallejo
Rosario Flores-Vallejo
GGGiorgio Gabarrini
Giorgio Gabarrini

30 October 2026 in Current Research in Microbial Sciences
Verified
Journal Article
Open access
MEMarines du Teil Espina
Marines du Teil Espina
RFRosario Flores-Vallejo
Rosario Flores-Vallejo
CHClaudia Hirschfeld
Claudia Hirschfeld
SGStefano Grasso
Stefano Grasso
PRPim Rozendal
Pim Rozendal
JDJan Maarten Van Dijl
Jan Maarten Van Dijl